This could represent an improvement when compared to formulations such as VMP00156 and Rv2125, which contain only sequences of PvCSP VK210 and VK247, as would confer higher protection against P. vivax-like infections, than that expected to be achieved through cross-reactivity from other CSP allelic variants. This evidence concerns the gene DNAJC5 and infection.